NCT03688555View on ClinicalTrials.gov

A Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 19, 2018

Primary Completion Date

November 24, 2020

Study Completion Date

December 1, 2020

Conditions
Bilateral Nasal Polyposis
Interventions
DRUG

ACT-774312

ACT-774312 will be available as hard gelatin capsules containing 200 mg of ACT-774312

DRUG

Placebo

Matching placebo hard gelatin capsules

Trial Locations (2)

9000

University Hospital Ghent, Ghent

10117

Charité Research Organisation GmbH, Berlin

Sponsors
All Listed Sponsors
lead

Idorsia Pharmaceuticals Ltd.

INDUSTRY

NCT03688555 - A Study to Evaluate the Effect of ACT-774312 in Subjects With Bilateral Nasal Polyposis | Biotech Hunter | Biotech Hunter